Opdivo Shows Promise in Phase 3 Trial for Hard-to-treat Gastric Cancer Patients
News
Patients with advanced or recurrent gastric cancers whose tumor is unable to be removed by surgery and who are intolerant or progressed following standard therapy may benefit from the anti-PD-1 agent ... Read more